Immunic (IMUX) stock
Follow IMUX's trial news. Pro members can get an alert when Immunic files news, and see its trials, share raises, and its CEO's filings.
What's next for IMUX, and how long its cash lasts
From Immunic’s SEC filings and ClinicalTrials.gov: the company’s own words, the registry’s dates, and arithmetic, not a forecast. Companies often miss their own dates.
Next step the company has named
Cash runway
About 7 quarters
Dilution on the horizon
- Shelf registration (S-3, filed Nov 22, 2023)
- At-the-market share sales program (424B5, filed Jun 10, 2024)
Insiders
No open-market buys or sales by its officers or directors in their filings of the last year.
FDA dates in the next 60 days
Decision dates and advisory committee meetings the companies have announced in their own filings, soonest first and small companies first.
- In 28 daysINOInovio Pharmaceuticals
INOINO-3107
- In 39 daysNRXPNRX Pharmaceuticals
NRXPDrug not named
- In 51 daysCAPRCapricor Therapeutics
CAPRDrug not named
Why it's down
Down 37% in 3 months, 31% under its 50-day average.
Down more than its industry: the 275 other stocks in it fell a median 11% over the same 3 months.
−3Long-term trend below a falling 200-day average, down over one year, down over two years
5 more things pulling IMUX's score down, for Pro members
What's next
Mon Oct 19: TOPRA Symposium 2026Industry event · date confirmed.
Expected to report Thu Nov 12, before the open
After its last 4 reports it closed +4.1% on average, higher 3 of 4 times.
1 more date ahead for Pro members: the conference
What would turn IMUX's score around: 8 things, for Pro members
Here is what Pro members see.
Every stock gets a card like this one, and a page with its price in real time, every line of its score, the chart, and its filings.
Nothing is firing on IMUX right now
One per group is shown here.
Also on the chart
- RSI 1425.6
- MACD (12, 26, 9)Below signal
- 50-day average$13.31
- 200-day average$11.34
- ADX 1444.2
- Support$8.50
- Resistance$8.70
- Bollinger Bands (20, 2)Inside
- Volume1.3x
How IMUX ranks in Biotech
IMUX is #274 of 276 by Quality Score. The top three are shown with their scores, and more by name.
KNSA7/1418
ABCL6/1416
OABI9/1415
IMCROpen for its score
IMTXOpen for its score
IMVTOpen for its score
INBXOpen for its score
IMUX0/14-10
When does IMUX report earnings, and what happens after?
Expected to report Thu Nov 12, before the open (in 41 days). Not yet confirmed by the company.
| Reported | When | Gap | Reaction | 5 sessions |
|---|---|---|---|---|
| Aug 11, 2026Before open | Before open | +0.9% | +9.8% | +13.7% |
| May 13, 2026Before open | Before open | -3.3% | +8.8% | -2.5% |
| Feb 26, 2026Before open | Before open | +1.5% | +4.1% | +28.5% |
| Nov 13, 2025Before open | Before open | +2.6% | -6.2% | -6.1% |
About Immunic
Immunic Inc is a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, including ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis, and psoriasis. The company is developing small molecule products, which include IMU-838, which is a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH; IMU-935 is an inverse agonist of RORyt, and IMU-856 targets the restoration of the intestinal barrier function. It operates in one segment which is Life science segment.
Every line of the score, on every stock.
- Real-time prices, no delay
- Every line of IMUX's score, with the points and the reason
- All 14 checks on IMUX and on all 2,958 stocks
- Every stock ranked, with the chart
- Every filing, and optional alerts on IMUX
Straight Answers.
Are the prices delayed?
Only on the public pages, which run at least 15 minutes behind. Pro members, trial included, see real-time prices: the scanner refreshes every 15 seconds, and your watchlist every few seconds, pre-market and after hours included.
Where does the data come from?
Daily bars, quotes, reference data, headlines, and short interest come from Massive, formerly Polygon, a licensed market data vendor. The age of the quotes is shown at the top of every page. Insider trades, notable holders and profits come straight from the SEC. That means Form 4 filings, 13F filings and XBRL financial data on EDGAR. Government filings come from the public STOCK Act and Office of Government Ethics disclosures. The market-wide headlines on the market line also come from the public headline feeds CNBC, MarketWatch and Yahoo Finance publish, shown as the headline, the source and a link to the article. Splits, dividends, and the financial statements on each ticker page come from the vendor's reference data. The 8-K filings on EDGAR are read for the items that move a price. Five years of history is loaded for every stock. So the 200-day and 52-week checks rest on real history. Options flow is not part of the product.
Do I need an account?
Not for the first 24 hours. Tap any green button and you're in, with no email and no password. To keep going, create a free account with Google, Apple, or your email. There is no password to make up.
Is this investment advice?
No. It is a screening tool that scores stocks on the chart, the company's own results, and the news and filings. It does not know your situation and it is not a recommendation to buy or sell anything. Please do your own research.